Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-15
2008-11-25
Coleman, Brenda L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S281000, C544S230000
Reexamination Certificate
active
07456186
ABSTRACT:
The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated β-amyloid deposits or β-amyloid levels in a patient.
REFERENCES:
patent: 4140793 (1979-02-01), Ward
patent: 4225613 (1980-09-01), Ward
patent: 6054457 (2000-04-01), Setoi et al.
patent: 6399824 (2002-06-01), Hofmeister et al.
patent: 6656957 (2003-12-01), Allgeier et al.
patent: 6689804 (2004-02-01), Wu et al.
patent: 6974829 (2005-12-01), Tung et al.
patent: 7285682 (2007-10-01), Hu
patent: 2005/0282825 (2005-12-01), Malamas et al.
patent: 2006/0111370 (2006-05-01), Zhu et al.
patent: 2006/0160828 (2006-07-01), Malamas et al.
patent: 2006/0173049 (2006-08-01), Malamas et al.
patent: 2006/0183790 (2006-08-01), Cole et al.
patent: 2006/0183792 (2006-08-01), Fobare et al.
patent: 2007/0004730 (2007-01-01), Zhou
patent: 2007/0004786 (2007-01-01), Malamas et al.
patent: 2007/0027199 (2007-02-01), Malamas et al.
patent: 2007/0072925 (2007-03-01), Malamas et al.
patent: 2007/0191431 (2007-08-01), Zhou
patent: 2007/0203116 (2007-08-01), Quagliato et al.
patent: 2008/0051390 (2008-02-01), Malamas et al.
patent: 0861831 (1998-09-01), None
patent: 2013192 (1979-08-01), None
patent: WO 97/45417 (1997-12-01), None
patent: WO 98/45267 (1998-10-01), None
patent: WO 01/87829 (2001-11-01), None
patent: WO 03/053938 (2003-07-01), None
patent: WO 03/064396 (2003-08-01), None
patent: WO 03/094854 (2003-11-01), None
patent: WO 2005/005412 (2005-01-01), None
patent: WO 2005/058311 (2005-06-01), None
patent: WO 2006/009653 (2006-01-01), None
patent: WO 2006/065277 (2006-06-01), None
patent: WO 2007/005404 (2007-01-01), None
patent: WO 2007/016012 (2007-02-01), None
Abbott e tal., Molecular Medicine Today, 1996, vol. 2, p. 106-113.
Allimony et al., “Synthesis and antimicrobial activity of some nitrogen heterobicyclic systems: Part I”, Indian Journal of Chemistry, 1999, vol. 38B, pp. 445-451.
Fact Sheet Alzheimer's Association, 2006.
Lefrance-Jullien et al., “Design and charaterization of a new cell-permeant inhibitor of the beta-secretase BACE1”, British Journal of Pharmacology, 2005, vol. 145, pp. 228-235.
Lyketsos et al., “Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer's Disease”, 2006, vol. 14, pp. 561-573.
Alzheimer's Disease, retrieved from internet on Jun. 27, 2007, http://www.mayoclinic.com/health/alzheimers-disease/DA00161/DSECTION-3.
National Institute of Neurological Disorders and Stroke, “Alzheimer's Disease Information Page”, retrieved from internet on Jun. 27, 2007, http://www.ninds.nih.gov/disorders/alzheimersdisease/alzheimersdisease.htm.
PCT Preliminary Report on Patentability, Written Opinion of the ISR, International Patent Application PCT/US2006/024793, International filing date Jun. 26, 2006.
PCT Preliminary Report on Patentability, Written Opinion of the ISR, International Patent Application PCT/US2006/024912, International filing date Jun. 26, 2006.
Selkoe, “Alzheimer's Disease: Genes, Proteins, and Therapy”, Physiological Reviews, 2001, vol. 81(2), pp. 741-766.
Su et al., “Drug delivery across the blood-brain barrier: why is it difficult? How to measure and improve it?”, Expert Opinion on Drug Delivery, Abstract, 2006, vol. 3, pp. 419-425.
Tao et al., “Synthesis of Conformationally constrained spirohydantoins with a Dibenzo[a,d]heptadiene ring”, Synthesis 2000, No. 10, pp. 1449-1453.
Vandana et al., “Transferring coupled liposomes as drug delivery carriers for brain trageting of 5-florouracil”, Journal of Drug Targeting, Abstract, 2005, vol. 13 pp. 245-250.
Varghese et al., “Human beta-secretase (BACE) and BACE Inhibitors”, J. Med. Chem. 2003, vol. 46(22), pp. 4625-4630.
Xiao et al., “An improved procedure for the synthesis of 4,4-disubstituted-3-oxo-1,2,5-thiadiazolidine 1,1-dioxides”, J. Heterocyclic Chem., 2000, vol. 37, pp. 773-777.
Yamada et al., “Hydantoin derivatives, I. Actions on central nervous system of 5,5-diarylhydantoins and 5,5-diarylhydantion-2-imines”, Abstract, Oyo Yakuri, 1975, vol. 9(6), pp. 841-847.
Barnes Keith Douglas
Erdei James J.
Gunawan Iwan S.
Hui Yu
Johnson Matthew Robert
Coleman Brenda L.
Dorigo Andrea
Larsen Scott
Moore Susanna
Silver Joel
LandOfFree
Diphenylimidazopyrimidines as inhibitors of β-secretase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diphenylimidazopyrimidines as inhibitors of β-secretase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diphenylimidazopyrimidines as inhibitors of β-secretase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4031050